login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First patient treated in Japan with Abbott’s Absorb BVS


Friday, 19 Aug 2011 15:19
Absorb bioresorbable vascular scaffold
Absorb bioresorbable vascular scaffold


The first patient in Japan has been treated with Abbotts’ Absorb bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND global clinical trial. To date, more than 300 patients in Europe, Latin America and Asia Pacific have been enrolled in this trial.


Absorb restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.


The first patient in Japan was treated in the ABSORB EXTEND clinical trial by Shigeru Saito, director, Cardiology and Catheterization Laboratories, and vice president, Shonan Kamakura Hospital, Kanagawa, Japan.


“Abbott’s BVS technology has the potential to open up a new therapy option for physicians treating patients with coronary artery disease in Japan,” said Saito. “For Japanese patients, this technology will hold tremendous appeal, as it is designed to treat a clogged blood vessel like a drug eluting stent and then dissolve, thereby restoring a more natural vessel function without leaving a permanent metallic implant behind in the body. Our hope is that our participation in the ABSORB EXTEND trial will be a meaningful contribution toward making this innovative technology available to patients in Japan.”


Absorb is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures. Because a permanent metallic implant is not left behind, a vessel treated with this device may ultimately have the ability to move, flex, pulsate and dilate. Restoration of these naturally occurring vessel functions is one of the features that makes this device a significant innovation for patients in the evaluation and treatment of coronary artery disease. In addition, continuing research will show whether the need to administer long-term dual anti-platelet therapy to patients is necessary once the temporary scaffold is metabolised.


The Absorb BVS received CE mark approval for the treatment of coronary artery disease and is under clinical investigation in several countries around the world.


About the ABSORB EXTEND clinical trial


The ABSORB EXTEND trial is a large-scale, single-arm trial that will enrol approximately 1,000 patients with complex coronary artery disease at up to 100 centres in Europe, Asia Pacific, Canada and Latin America.


Data from this trial may be used to support approval in various markets around the world. Key endpoints of the study include assessments of safety - major adverse cardiac events (MACE) and treated-site thrombosis rates - at 30 days and at six, 12, 24 and 36 months, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system. Other key endpoints in a sub-group study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other imaging modalities.




Add New Comment

Related Items


Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies
Friday, 31 Jul 2015
Abbott Vascular has announced it has entered into an agreement to purchase Tendyne Holdings (focused on developing minimally invasive mitral valve replacement therapies) and secured an option to ... Abbott Vascular expands its  structural heart portfolio with new mitral valve technologies

Features


Bifurcation lesions: When a two-stent technique is needed
Tuesday, 18 Aug 2015
The advent of second-generation drug-eluting stents and the associated improved safety and efficacy has meant that the risks of using two stents for bifurcation lesions has significantly decreased. M... Bifurcation lesions: When a two-stent technique is needed

Getting to grips with social media
Tuesday, 04 Aug 2015
Pascal Meier believes that social media is the logical next step from the internet—just as the internet has revolutionised connectivity, social media is revolutionising communication. In this ... Getting to grips with social media

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions